Loading…
Loading…
The Columbia Seligman Premium Technology Growth Fund (STK) offers strong total returns, outperforming comparable ETFs like TDVI, and currently trades at a 6.57% discount to NAV. STK's active management and AI hardware exposure drive outperformance, but increase risk in tech downturns; TDVI provides more conservative, income-focused exposure with monthly distributions. STK's dynamic option strategy and capital gains support variable payouts, while TDVI's index-limited holdings restrict upside but offer steadier income for lifestyle investors.
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced two presentations of data for STK-002 at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting, taking place October 9-12 in New Orleans. STK-002 represents a novel approach to Autosomal Dominant Optic Atrophy (ADOA), the most common inherited optic nerve disorder, by targeting.
BOSTON--(BUSINESS WIRE)--Today, Columbia Seligman Premium Technology Growth Fund, Inc. (NYSE: STK) (the Fund) declared a fourth-quarter distribution, pursuant to its managed distribution policy, in the amount of $0.4625 per share, which is equal to a quarterly rate of 2.3125% (9.25% annualized) of the $20.00 offering price in the Fund's initial public offering in November 2009. The fourth-quarter distribution of $0.4625 per share is equal to a quarterly rate of 0.8601% (3.44% annualized) of the.
BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced two presentations of data for STK-002 at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting, taking place October 9-12 in New Orleans. STK-002 is an investigational medicine designed to target the underlying cause of Autosomal Dominant Optic Atrophy (ADOA) by increasing OPA1.
Not everyone wants to or needs to retire early. After all, a 9-5 day job brings steady income, a sense of purpose and discipline, and keeps one engaged in physical and mental activity. Still, one size does not fit all. There would be many folks who like the idea of retiring from a 9-5 job in their 40s or early 50s and pursuing something they have always dreamt about. We will discuss what it really takes to retire early and how to go about investing for early retirement, also known as FIRE (Financially Independent Retire Early).
Columbia Seligman Premium Technology Growth Fund offers active tech exposure with a current 6.9% discount to NAV, wider than its historical average. STK's concentrated portfolio and call-writing strategy have driven strong outperformance versus SPY and QQQ but introduce single-stock and upside-capping risks. Dividend yield stands at 3.47%, primarily funded by capital gains and option premiums rather than portfolio income.
I remain bullish on AI-driven growth, favoring a diversified, income-oriented portfolio to capture sustained sector upside while mitigating bubble risks. Shifts from R&D to CAPEX among hyperscalers and evolving chip utility support a durable earnings expansion, not just accounting-driven EPS growth. My core AI income sleeve blends STK, SMH, UTG, and BUI, targeting a consistent ~4.2% yield with annual rebalancing for risk control and capital appreciation.
BOSTON--(BUSINESS WIRE)--Today, Columbia Seligman Premium Technology Growth Fund, Inc. (NYSE: STK) (the Fund) declared a third-quarter distribution, pursuant to its managed distribution policy, in the amount of $0.4625 per share, which is equal to a quarterly rate of 2.3125% (9.25% annualized) of the $20.00 offering price in the Fund's initial public offering in November 2009. The third-quarter distribution of $0.4625 per share is equal to a quarterly rate of 0.9421% (3.77% annualized) of the F.